Benedetta Bolognesi, junior group leader at IBEC, appears in different media for a recent study published in the eLife magazine. In the study they show the first map with all the possible mutations in the amyloid beta peptide and tested how they influence its aggregation into plaques, a pathological hallmark of Alzheimer’s disease.
The study has been carried out by researchers from the Institute for Bioengineering of Catalonia (IBEC) in collaboration with the Center for Genomic Regulation (CRG). The comprehensive mutation map, which is the first of its kind, has the potential to help clinical geneticists predict whether the mutations found in amyloid beta can make an individual more prone to developing Alzheimer’s disease later in life.
Similar maps have been built for the BRCA1 gene and breast cancer in the past and it is exciting we can replicate this for Alzheimer’s disease.
Benedetta Bolognesi, junior group leader at IBEC
You can read the full articles here: